Actively Recruiting
Evaluating Elacestrant Monotherapy in Japanese Adults with Advanced ERHER2- Breast Cancer With ESR1 Mutation After CDK46 Inhibitor Therapy
Led by Stemline Therapeutics, Inc. · Updated on 2026-10-13
70
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the drug elacestrant in Japanese post-menopausal women and men with advanced or metastatic breast cancer that is estrogen receptor positive ER and human epidermal growth factor receptor 2 negative HER2-, who also have a specific gene mutation known as ESR1. These participants must have experienced disease progression after 1 to 2 prior endocrine therapy treatments for metastatic breast cancer, including therapy with a CDK46 inhibitor combined with fulvestrant or an aromatase inhibitor. The study is an open-label Phase 2 trial aimed at assessing elacestrants efficacy and safety. Participants will receive elacestrant as a once-daily oral tablet. This is a single-arm study without a placebo group, focusing on treatment with elacestrant. The study will continue for up to approximately 27 months to monitor treatment effects and safety. During the study, participants will undergo evaluations including imaging assessments to measure progression-free survival, adverse event monitoring, and blood tests to measure plasma concentrations of elacestrant. Researchers will also observe overall survival and progression-free survival as assessed by investigators. The total duration for participant involvement aligns with the treatment and follow-up period of up to about 27 months.
CONDITIONS
Brief Title
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
Research Team
S
Stemline Trials
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here